Moderna and SpaceX highlighted by fast-growing US fund traded in London
[ad_1] Baillie Gifford US Growth Trust devoted much of its semi-annual report to the prospects for Moderna biotech and the SpaceX rocket launcher, two of its investments that helped increase its net asset value during this period. The USA fund, + 2.15%, a component of the FTSE 250 MCX, + 0.19%, reported that the net … Read more